Satellos Bioscience Inc MSCL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
-
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
-
Satellos to Present at the 31st Annual Congress of the World Muscle Society
-
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
-
Satellos to Participate in Upcoming Investor Conferences
-
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
-
Satellos Bioscience Shares Climb After FDA Fast Track Designation
Trading Information
- Previous Close Price
- CA$9.79
- Day Range
- CA$9.25–10.00
- 52-Week Range
- CA$7.56–18.98
- Bid/Ask
- CA$9.01 / CA$11.52
- Shares Outstanding
- 21.22M
- Market Cap
- CA$196.25M
- Volume/Avg
- 13,239 / 14,947
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 21
- Website
- https://www.satellos.com
Valuation
|
Metric
|
MSCL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.34 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MSCL
|
|---|---|
Quick Ratio | 10.68 |
Current Ratio | 11.22 |
Interest Coverage | — |
Quick Ratio
MSCL
Profitability
|
Metric
|
MSCL
|
|---|---|
Return on Assets (Normalized) | −62.88% |
Return on Equity (Normalized) | −110.19% |
Return on Invested Capital (Normalized) | −71.49% |
Return on Assets
MSCL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?Sc@^L! | LOCK|jdf!& | $127B | |||
| Moderna Inc
MRNA
| LOCK|!kkQL?^ | LOCK|!#^ | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?HS%%@X | LOCK|n%@b | $81B | |||
| argenx SE ADR
ARGX
| LOCK|LH#Q&r | LOCK|TP | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?!&>D? | LOCK|#P& | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&t@lF& | LOCK|m!kk | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$B!S@nf$ | LOCK|tNlg# | $27B | |||
| Incyte Corp
INCY
| LOCK|^^rLQJw | LOCK|nLh | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|%#ZFGq | LOCK|r^S | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>whfx&G | LOCK|^t | $14B |
United States